Molecular Biosystems, Shionogi deal

MB reacquired from Shionogi all rights to manufacture, market and sell its Albunex family of products in Japan, Taiwan and South Korea. Under the agreement, MBI paid $3 million to Shionogi and will pay an additional $5.5 million over the next three years.

The agreement settles a dispute between the companies concerning the license and distribution agreement for Albunex, an ultrasound contrast agent, and results in the dismissal of all claims raised by the companies in a pending arbitration. ...